Redx Pharma Announces First Patient Dosed in Phase 1/2a

Redx Pharma has commenced a Phase I study for a novel cancer treatment at The Christie in Manchester.

The compound, RXC004, is a novel, oral, potent small molecule Porcupine inhibitor, and targets the Wnt pathway that is implicated in the maintenance of cancer stem cells.

ApconiX were proud to work with our Redx colleagues in reaching this important milestone, by providing project toxicology support.

By | 2018-02-14T10:01:35+00:00 February 13th, 2018|Alliances, Expertise, News, Toxicology, Uncategorised|0 Comments

About the Author:

Leave A Comment